Your browser is no longer supported. Please, upgrade your browser.
PHIO Phio Pharmaceuticals Corp. monthly Stock Chart
PHIO [NASD]
Phio Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-16.25 Insider Own0.30% Shs Outstand1.77M Perf Week12.77%
Market Cap8.96M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float- Perf Month32.50%
Income-9.10M PEG- EPS next Q-0.73 Inst Own20.90% Short Float- Perf Quarter-15.06%
Sales0.00M P/S- EPS this Y66.40% Inst Trans- Short Ratio0.15 Perf Half Y-66.12%
Book/sh6.76 P/B0.39 EPS next Y90.00% ROA-82.10% Target Price- Perf Year-88.87%
Cash/sh3.93 P/C0.67 EPS next 5Y- ROE-104.30% 52W Range1.60 - 25.30 Perf YTD-71.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.53% Beta1.95
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low65.63% ATR0.48
Employees11 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)59.22 Volatility31.39% 15.87%
OptionableNo Debt/Eq0.00 EPS Q/Q76.80% Profit Margin- Rel Volume0.56 Prev Close2.72
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.35M Price2.65
Recom- SMA209.75% SMA5026.06% SMA200-68.24% Volume754,361 Change-2.57%
May-29-20 08:00AM  
05:38AM  
May-14-20 04:05PM  
May-12-20 04:38PM  
May-04-20 07:30AM  
Apr-07-20 06:05AM  
Apr-02-20 12:15PM  
Mar-31-20 12:11PM  
07:30AM  
Mar-26-20 05:33PM  
Mar-11-20 08:03AM  
Mar-10-20 05:06PM  
Feb-13-20 05:20PM  
Feb-12-20 09:18AM  
Feb-11-20 09:15AM  
Feb-10-20 08:00AM  
Feb-06-20 12:30PM  
Feb-05-20 09:00AM  
Jan-14-20 12:55PM  
Jan-06-20 07:30AM  
Dec-13-19 08:00AM  
Nov-21-19 07:30AM  
Nov-20-19 05:30PM  
Nov-19-19 07:56AM  
Nov-18-19 07:00AM  
Nov-13-19 04:11PM  
11:29AM  
08:05AM  
Nov-12-19 07:45AM  
Oct-29-19 08:05AM  
Oct-11-19 08:00AM  
Sep-09-19 07:10AM  
Sep-03-19 07:10AM  
Aug-26-19 11:30AM  
Aug-15-19 07:05AM  
Aug-12-19 05:10PM  
Jun-12-19 10:30AM  
May-20-19 07:05AM  
May-14-19 05:15PM  
Apr-22-19 10:15AM  
Apr-12-19 09:32AM  
Apr-10-19 07:05AM  
Mar-28-19 07:05AM  
Mar-27-19 05:20PM  
Mar-25-19 07:05AM  
Feb-15-19 07:15AM  
Dec-18-18 07:05AM  
Dec-04-18 07:05AM  
Dec-03-18 11:30AM  
Nov-19-18 07:00AM  
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum Munchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.